Phase 3 clinical trial

Pharvaris raises $115M through 3.87M share offering at $29.68 per share to advance oral angioedema treatments; Phase 3 data expected Q3 2026.

ABLi Therapeutics appoints Dr. Rachelle Doody, Roche neurology veteran, to board as company advances risvodetinib into Phase 3 trials for Parkinson's and related diseases.

Avalo Therapeutics prices $375M offering of 19.73M shares at $17.75 each to fund Phase 3 development of hidradenitis suppurativa treatment abdakibart, closing May 7, 2026.

BioCryst secures $70M upfront plus $275M milestone payments for navenibart European rights, reinforcing strategy to focus on U.S. commercialization.

Tenax Therapeutics appoints veteran pharma executive Timothy Healey as Chief Commercial Officer to lead TNX-103 market launch preparations as Phase 3 trials advance.

Oculis to present advancing ophthalmology pipeline at ARVO 2026, with Phase 3 OCS-01 DME results expected June 2026.

Mesoblast completes recruitment of 300+ patients in pivotal Phase 3 trial for chronic back pain therapy, targeting mid-2027 results and Q3 2027 FDA filing.

Rosen Law Firm sues Gossamer Bio ($GOSS) over alleged misstatements about Phase 3 trial design. Lead plaintiff deadline: June 1, 2026.

Xenon Pharmaceuticals reports positive Phase 3 data for azetukalner in focal onset seizures, with 53.2% seizure reduction versus 10.4% placebo. FDA submission planned for Q3 2026.

BioVersys will present Phase 3 data for BV100 and collaborate data for BV500 at ESCMID 2026, advancing its antibiotic-resistant infection pipeline.

Opus Genetics will present three abstracts at ASCRS 2026, including Phase 3 results for phentolamine ophthalmic solution treating presbyopia and mesopic vision issues.

Inventiva filed 2025 regulatory documents with €99.3M cash on hand, advancing lanifibranor Phase 3 trial for metabolic liver disease treatment.

Inventiva filed 2025 regulatory documents showing €230.9M cash reserves and €4.5M revenues while advancing lanifibranor in Phase 3 MASH trials.

Soligenix reported zero 2025 revenue and $11.1M net loss. Company has $7.9M cash, seeking partnerships to fund operations through Q4 2026 pivotal trials.

MoonLake reports Week 40 Phase 3 data for sonelokimab showing 62% HiSCR75 response rates in hidradenitis suppurativa with no new safety signals.

Biotech firm Humacyte reported $2M in 2025 revenues from 61 Symvess unit sales, secured Saudi Arabia commitment, and targets critical Phase 3 results in Q2 2026.

Viking Therapeutics finishes enrolling 1,000 patients in Phase 3 VANQUISH-2 trial of VK2735 for obesity treatment, with results expected in 2027.

$IMNN to discuss 2025 results and OVATION 3 Phase 3 trial progress for IMNN-001 ovarian cancer immunotherapy on March 31, 2026.

Sol-Gel Technologies prices 459,112 shares at $72 each, raising $33.1M for SGT-610 development in Gorlin syndrome treatment.

Inventiva to release 2025 financial results March 30, 2026, as its lanifibranor MASH drug advances through Phase 3 clinical trials.